GM2 Gangliosidosis
Neurology·MeSH: Gangliosidoses, GM2
Prevalence
5.0 / 100K
2 drugs in development·2 companies·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| plx-300 | Polaryx Therapeutics Inc. (PLYX) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| axo-aav-gm2 | Sio Gene Therapies Inc. (SIOX) |
Compare drugs
Frequently asked questions
How many drugs are in development for GM2 Gangliosidosis?
BioSniper tracks 2 drugs in development for GM2 Gangliosidosis across 2 companies.
How many clinical trials target GM2 Gangliosidosis?
There are 3 clinical trials targeting GM2 Gangliosidosis tracked by BioSniper.
What is the prevalence of GM2 Gangliosidosis?
The estimated prevalence of GM2 Gangliosidosis is approximately 5.0 per 100,000 population.
Deep-dive into GM2 Gangliosidosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis